Optimising antiplatelet utilisation in the acute care setting: a novel threshold for medical intervention in suspected acute coronary syndromes.
Charlie ReynardNiall MorrisPhil MossHeather JarmanJessica JanePublished in: Emergency medicine journal : EMJ (2019)
Treatment with ticagrelor appears to yield greater net benefit for patients when the probability of ACS >8%. The clinical and cost-effectiveness of this 'precision medicine' approach warrants further study.
Keyphrases
- acute coronary syndrome
- acute care
- end stage renal disease
- percutaneous coronary intervention
- randomized controlled trial
- ejection fraction
- antiplatelet therapy
- chronic kidney disease
- newly diagnosed
- healthcare
- peritoneal dialysis
- pulmonary embolism
- st segment elevation myocardial infarction
- patient reported outcomes